Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CISH-inactivated TILs in metastatic NSCLC
NCT05566223Phase 2Withdrawn
- Sponsor
- Intima Bioscience
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Gene Silencing, CRISPR-Cas9, Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of cish inactivated til in non-small cell lung cancer (NSCLC), sponsored by Intima Bioscience. Planned start Feb 2023; status: withdrawn.
02
Drugs
cish inactivated til
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05566223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566223.